Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Enovis Corp

Healthcare US ENOV

21.56USD
-0.38(1.73%)

Last update at 2026-06-03T20:00:00Z

Day Range

21.3122.39
LowHigh

52 Week Range

21.0037.85
LowHigh

Fundamentals

  • Previous Close 21.94
  • Market Cap1365.40M
  • Volume1040921
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA369.17M
  • Revenue TTM2248.05M
  • Revenue Per Share TTM39.39
  • Gross Profit TTM 1368.72M
  • Diluted EPS TTM-20.72

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1159.41800M -822.92400M -67.12800M -2.06900M 165.39M
Minority interest -0.82000M -0.67900M -0.53000M -1.53300M -4.62100M
Net income -1184.44000M -825.49400M -33.26100M -38.18900M 98.69M
Selling general administrative 1070.15M 1027.35M 830.30M 772.91M 1329.38M
Selling and marketing expenses - - - - -
Gross profit 1345.26M 1180.76M 990.78M 869.38M 1613.66M
Reconciled depreciation 294.38M 284.80M 217.10M 219.71M 262.92M
Ebit -1124.59500M -765.82400M -47.37900M -88.57000M 256.64M
Ebitda -830.21700M -481.02800M 169.73M 131.14M 558.41M
Depreciation and amortization 294.38M 284.80M 217.11M 219.71M 301.77M
Non operating income net other - - - -18.30800M -29.87000M
Operating income -1181.71100M -775.71900M -65.70900M -88.57000M 256.64M
Other operating expenses 3429.76M 2883.34M 1772.91M 1653.76M 3570.02M
Interest expense 34.82M 57.10M 19.75M 24.05M 72.59M
Tax provision 22.29M 4.49M -13.28900M 36.12M 66.69M
Interest income - - - - -
Net interest income -34.82300M -57.10000M -19.74900M -24.05200M -72.59300M
Extraordinary items - - - - -
Non recurring - - - -19.48000M 27.64M
Other items - - - - -
Income tax expense 22.29M 4.49M -13.28900M 36.12M 66.69M
Total revenue 2248.05M 2107.62M 1707.20M 1563.10M 3854.30M
Total operating expenses 2526.97M 1956.47M 1056.49M 960.04M 1329.38M
Cost of revenue 902.79M 926.87M 716.42M 693.72M 2240.64M
Total other income expense net 22.29M -47.20500M -1.41900M 86.50M -91.25500M
Discontinued operations - - - 26.43M -22.41500M
Net income from continuing ops -1181.71100M -827.41600M -53.83900M -38.18900M 98.69M
Net income applicable to common shares - - - -13.29200M 71.66M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3834.74M 4718.78M 4509.33M 4273.25M 8515.34M
Intangible assets 1236.71M 1317.43M 1127.36M 1110.73M 1675.46M
Earning assets - - - - -
Other current assets 143.50M 144.13M 100.01M 48.16M 90.73M
Total liab 2342.84M 2154.45M 1088.63M 823.45M 3853.91M
Total stockholder equity 1489.64M 2562.26M 3418.39M 3448.09M 4617.38M
Deferred long term liab - - - 4.50M 5.20M
Other current liab 344.71M 279.96M 198.23M 206.73M 479.63M
Common stock 0.06M 0.06M 0.06M 0.05M 0.16M
Capital stock 0.06M 0.06M 0.06M 0.05M 0.16M
Retained earnings -1467.46300M -283.02300M 542.47M 575.73M 589.02M
Other liab - - - 166.99M 606.32M
Good will 718.30M 1692.71M 2060.89M 1983.59M 3467.30M
Other assets - - - 63.79M 363.49M
Cash 36.39M 48.17M 36.19M 24.30M 719.37M
Cash and equivalents - - - - -
Total current liabilities 598.47M 529.00M 369.61M 565.20M 1023.58M
Current deferred revenue 6.50M 6.23M 2.95M 3.56M 31.47M
Net debt 1343.15M 1356.13M 500.23M 286.24M 1512.95M
Short term debt 59.74M 42.37M 21.57M 219.28M 8.31M
Short long term debt 35.00M 20.03M - 219.28M 8.31M
Short long term debt total 1379.54M 1404.30M 536.42M 310.54M 2232.32M
Other stockholder equity 3048.41M 2973.12M 2900.75M 2925.73M 4544.21M
Property plant equipment - - - 236.74M 705.82M
Total current assets 1207.06M 1146.45M 896.52M 795.02M 2303.28M
Long term investments - - - - -
Net tangible assets - - - 353.77M -525.37900M
Short term investments - - - - -
Net receivables 442.79M 407.03M 291.48M 267.38M 638.70M
Long term debt 1261.79M 1309.47M 466.16M 40.00M 2078.68M
Inventory 584.38M 547.12M 468.83M 426.64M 776.29M
Accounts payable 187.53M 179.10M 132.47M 135.63M 504.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 1.72M 44.05M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -91.36300M -127.89200M -24.88100M -53.43000M -516.01300M
Additional paid in capital - - - - -
Common stock total equity - - - 0.05M 0.16M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 575.73M 589.02M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 71.95M 68.38M 90.25M 80.29M 363.49M
Deferred long term asset charges - - - - -
Non current assets total 2627.68M 3572.33M 3612.82M 3478.22M 6212.07M
Capital lease obligations 82.74M 74.80M 70.25M 51.26M 187.73M
Long term debt total - - - 40.00M 2078.68M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 1.60M -955.47300M -220.17100M -176.38800M -320.47600M
Change to liabilities - - - -11.84300M 178.47M
Total cashflows from investing activities -179.37100M -955.47300M -242.46700M -176.38800M -320.47600M
Net borrowings -36.92500M 859.23M 217.19M -1606.80300M -126.03200M
Total cash from financing activities -52.40000M 846.82M 127.80M -465.12700M 584.91M
Change to operating activities - - - -46.46400M 45.38M
Net income -1183.62000M -824.81500M -33.26100M -11.75900M 76.28M
Change in cash -11.77800M 3.33M 20.54M -695.07500M 618.30M
Begin period cash flow 48.17M 44.83M 24.30M 719.37M 101.07M
End period cash flow 36.39M 48.17M 44.83M 24.30M 719.37M
Total cash from operating activities 217.29M 113.50M 134.99M -55.86100M 356.10M
Issuance of capital stock 1.32M 1.87M 4.77M 5.81M 745.18M
Depreciation 294.38M 284.80M 217.10M 219.71M 262.92M
Other cashflows from investing activities 1.60M -4.84500M 32.57M -70.93800M -216.23900M
Dividends paid - - - - -
Change to inventory -11.98100M 39.07M -24.73700M -118.79100M -129.96700M
Change to account receivables -10.75200M -57.05100M -16.31600M -45.18900M -110.98500M
Sale purchase of stock - -4.77200M - 5.81M 745.18M
Other cashflows from financing activities -10.11900M -9.50800M -91.17400M 1120.22M 957.25M
Change to netincome - - - 61.14M 41.42M
Capital expenditures 197.38M 180.71M 122.22M 105.45M 104.24M
Change receivables - - - -45.18900M -110.98500M
Cash flows other operating - - - -149.13300M 34.18M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -697.37600M 620.53M
Change in working capital 15.46M -13.92900M -27.26800M -220.49400M -17.10100M
Stock based compensation 32.92M 29.66M 34.06M 38.95M 35.35M
Other non cash items 1060.37M 647.81M -28.23600M -88.59300M 20.84M
Free cash flow 19.92M -67.21000M 12.77M -161.31100M 251.86M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ENOV
Enovis Corp		 -0.38 1.73% 21.56 - 7.14 0.61 1.01 1.27 22.42
ABT
Abbott Laboratories		 0.02 0.02% 86.99 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 1.70 0.58% 295.00 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 4.20 5.69% 77.95 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.01 0.02% 47.69 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Enovis Corp

2711 Centerville Road, Wilmington, DE, United States, 19808

Key Executives

Name Title Year Born
Mr. Mitchell P. Rales Co-Founder & Independent Chairman 1957
Mr. Matthew L. Trerotola CEO & Director 1967
Mr. Brady R. Shirley Pres, COO & Director 1966
Mr. Christopher M. Hix Exec. VP of Fin. & CFO 1962
Mr. Daniel A. Pryor Exec. VP of Strategy & Bus. Devel. 1968
Mr. John Kleckner Principal Accounting Officer 1977
Mr. Michael S. Macek VP of Fin. & Investor Relations 1972
Mr. Bradley J. Tandy Sr. VP & Gen. Counsel 1959
Katie Sweet VP of Corp. Communication NA
Ms. Patricia A. Lang Sr. VP & Chief HR Officer 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.